VJOncology: ChemoID trial shows increased survival for glioma patients
UC's Soma Sengupta discusses study results at recent conference
A new collaborative Phase III trial has shown increased survival for patients with recurrent high-grade glioma (HGG), a type of fast-spreading brain tumor.
Soma Sengupta, MD, PhD, was interviewed discussing the results of the trial at the American Association for Cancer Research Meeting 2022 with Pier Paolo Claudio, MD, PhD, the inventor of the ChemoID assay, which is CLIA-certified for glioblastoma. Claudio is a professor at the University of Mississippi, and the two were featured by the Video Journal of Oncology (VJOncology).
The trial examined the effectiveness of a platform called ChemoID, a cancer stem cell test. ChemoID is an actionable tool doctors can use to help determine which treatment is most effective for an individual patient's particular type of tumor.
ChemoID highlights which cancer stem cells are responsible for the tumor coming back or growing, so doctors can then choose a therapy that targets those particular stem cells. The platform was compared against the typical standard where physicians choose what they think will be the best therapy.
"The study was amazing in that most recurrent high grade glioma trials don't show an improvement in survival, but this one showed a three and a half month improvement in survival," said Sengupta, University of Cincinnati associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist, funded by the Harold C. Schott Endowed Chair in Molecular Therapeutics (Neurosurgery) and the Pam and Tom Mischell Funds.
Once the research is accepted and published, the ChemoID platform can be implemented in clinical pathology laboratories.
Watch the VJOncology interview.
Sengupta and Claudio were also featured in a VJOncology video discussing other potential methods for prolonging the life of HGG patients. Watch the second interview.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
Bearcat Mascot, Cheer Team and scholarships help celebrate Decision Day
December 12, 2025
Cincinnati media organization provided news coverage of Decision Day activities at the University of Cincinnati on Dec. 10, 2025. Surprise announcements of the 2026 Marian Spencer Scholarship recipient occurred during the day.